1. The Effect of Methylphenidate on Fatigue in Advanced Cancer: An Aggregated N-of-1 Trial 
Geoffrey K. Mitchell, PhD, FRACGP, FAChPM, Janet R. Hardy, MD, FRACP, Catherine J. Nikles, MBBS, PhD, Sue-Ann S. Carmont, BA(Hons), Hugh E. Senior, PhD, Philip J. Schluter, PhD, Phillip Good, PhD, FRACP, David C. Currow, FRACP, MPH 
Journal of Pain and Symptom Management 
Volume 50, Issue 3, Pages (September 2015)
DOI: /j.jpainsymman
Copyright © Terms and Conditions

2. Fig. 1
Typical N-of-1 study. The order of treatment and placebo are randomly assigned for each cycle.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions

3. Fig. 2
Patient flowchart, showing timing of, and reasons for, withdrawal.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions

4. Fig. 3
a) Mean difference (95% credible intervals [CIs]) between methylphenidate (MPH) compared with placebo on individual fatigue scores (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F]) for each patient (circle) and the overall group (square). b) Mean difference (95% CIs) between MPH compared with placebo on individual Wu Cancer Fatigue Scale scores for each patient (circle) and the overall group (square). c) Mean difference (95% CIs) between MPH compared with placebo on individual Edinburgh Depression Scale scores for each patient (circle) and the overall group (square). a–c) Note: the solid black circles designate positive responders, the hollow circles designate nonresponders, and the solid gray circle designates a negative responder.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © Terms and Conditions